On Monday, shares of Antares Pharma, Inc. (NASDAQ:ATRS) marked $3.62 per share versus a previous $3.67 closing price. With having a -1.36% loss, an insight into the fundamental values of Antares Pharma, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ATRS showed a fall of -22.98% within its YTD performance, with highs and lows between $2.60 – $5.13 during the period of 52 weeks, compared to the simple moving average of 2.27% in the period of the last 200 days.
H.C. Wainwright equity researchers changed the status of Antares Pharma, Inc. (NASDAQ: ATRS) shares to a “Buy” rating in the report published on October 23rd, 2017. Other analysts, including H.C. Wainwright, also published their reports on ATRS shares. H.C. Wainwright repeated the rating from the previous report, marking ATRS under “Buy” rating, in the report published on June 23rd, 2017. Additionally, ATRS shares got another “Strong Buy” rating from Raymond James. On May 28th, 2015, Jefferies Initiated an Buy rating and increased its price target to $5. On the other hand, Piper Jaffray Initiated the “Overweight” rating for ATRS shares, as published in the report on May 18th, 2015. Ladenburg Thalmann seems to be going bullish on the price of ATRS shares, based on the price prediction for ATRS, indicating that the shares will jump from $5 to $5.75, giving the shares “Buy” rating based on their report from August 8th, 2013. Another “Outperform” rating came from Oppenheimer, providing a prediction for $5.75 price target according to the report published in June 21st, 2013.
The present dividend yield for ATRS owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording 91.60%, hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of Antares Pharma, Inc. (ATRS) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -1.40% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 2.50 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ATRS is currently recording an average of 1.96M in volumes. The volatility of the stock on monthly basis is set at 4.11%, while the weekly volatility levels are marked at 4.77%with -9.95% of loss in the last seven days. Additionally, long-term investors are predicting the target price of $6.44, indicating growth from the present price of $3.62, which can represent yet another valuable research and analysis points that can help you decide whether to invest in ATRS or pass.
Antares Pharma, Inc. (ATRS) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ATRS shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Antares Pharma, Inc., while the value 41.61 can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value 0.00 is supported by the yearly ESP growth of 61.40%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 1.50%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 40.40% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.Are Institutional Investors Increasing Stakes in ATRS Shares?
It appears that more than several institutional investors and hedge funds decided to increase stakes in ATRS in the recent period. That is how BlackRock Fund Advisors now has an increase position in ATRS by 2.90% in the first quarter, owning 10.17 million shares of ATRS stocks, with the value of $47.79 million after the purchase of an additional 286,985 shares during the last quarter. In the meanwhile, The Vanguard Group, Inc. also increased their stake in ATRS shares changed 6.31% in the first quarter, which means that the company now owns 7.52 million shares of company, all valued at $35.37 million after the acquisition of additional 446,916 shares during the last quarter.
Sargent Investment Group LLC acquired a new position in Antares Pharma, Inc. during the first quarter, with the value of $17.66 million, and Northern Trust Investments, Inc. increased their stake in the company’s shares by 24.17% in the first quarter, now owning 434,901 shares valued at $10.5 million after the acquisition of the additional 2.23 million shares during the last quarter. In the end, Geode Capital Management LLC increased their position by — during the first quarter, now owning 2.05 million ATRS shares, now holding the value of $9.64 million in ATRS with the purchase of the additional 101,862 shares during the period of the last quarter. At the present, 40.40% of ATRS shares are in the ownership of institutional investors.